Threshold Pharmaceuticals Inc (THLD.PH) Key Developments |
United States

Threshold Pharmaceuticals Inc (THLD.PH)

THLD.PH on Philadelphia Stock Exchange

1 Jul 2016
Change (% chg)

$0.06 (+9.05%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Threshold Pharmaceuticals Inc announces workforce reduction
Friday, 18 Dec 2015 04:17pm EST 

Threshold Pharmaceuticals Inc:Announces workforce reduction.Says will reduce its workforce by approximately two-thirds, resulting in between 20-25 remaining employees.Anticipates one-time severance-related charge associated with workforce reduction to be about $2.6 million.Says the majority of the charges will be paid by the end of the first quarter of 2016.Sees one-time severance-related charge associated with workforce reduction to be about $2.6 million.Enacting reduction in workforce as a result of outcomes from two phase 3 trials of evofosfamide.Says Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA.  Full Article

Threshold Pharmaceuticals Inc - Merck KGaA, Threshold drug fails in late-stage cancer trials - Reuters
Sunday, 6 Dec 2015 10:11pm EST 

Threshold Pharmaceuticals Inc:Merck KGaA MRCG.DE and development partner Threshold Pharmaceuticals THLD.O said their experimental cancer drug evofosfamide failed to extend lives in two late-stage clinical studies, a major setback for both firms - RTRS.Evofosfamide did not meet the main goal of improving survival in patients suffering from advanced pancreatic cancer and advanced soft tissue sarcoma, prompting the two companies to give up exploring the drug's use against these cancer forms. - RTRS.Merck said on Monday it would focus efforts on more promising candidates in its drug pipeline and would soon decide about evofosfamide's overall future - RTRS.The new disappointment leaves CEO-designate Stefan Oschmann, a pharmaceuticals expert, with a narrow drug development pipeline that rests mainly on cancer immune therapy avelumab, jointly developed with Pfizer - RTRS.  Full Article

Threshold Pharmaceuticals Inc enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany
Wednesday, 18 Nov 2015 07:00am EST 

Threshold Pharmaceuticals Inc:Enters into definitive co-promotion agreement for evofosfamide with Merck KGaA, Darmstadt, Germany.Says may co-promote evofosfamide in the U.S. subject to FDA approval of evofosfamide.Development milestone payment, royalty payment portions of the license and co-commercialization agreement remain the same.Threshold expects to announce top-line data from evofosfamide phase 3 clinical trials around the end of 2015.  Full Article

Threshold Pharmaceuticals Initiates Phase 2 Clinical Trial of Tarloxotinib Bromide
Thursday, 27 Aug 2015 07:00am EDT 

Threshold Pharmaceuticals Inc:Announces that the company has initiated a Phase 2 clinical trial of tarloxotinib bromide, or 'tarloxotinib' (TH-4000), for the treatment of patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) or skin (SCCS).  Full Article

Threshold Pharmaceuticals Inc announces pricing of $30 mln offering of common stock and warrants
Thursday, 12 Feb 2015 06:00am EST 

Threshold Pharmaceuticals Inc:Says pricing of an underwritten offering of 8,300,000 shares of its common stock together with accompanying warrants to purchase an aggregate of 8,300,000 shares of common stock.Combined offering price of each share of common stock and accompanying warrant was $3.62.Says net proceeds to Threshold from this offering are expected to be about $28.2 mln, after deducting underwriting discounts and commissions and estimated offering expenses payable by company.Expects to use net proceeds from this offering for working capital and general corporate purposes, including research and development expenses, general and administrative expenses and manufacturing expenses.Jefferies LLC is acting as sole book-running manager for the offering. H.C. Wainwright & Co., LLC. is acting as lead manager for offering.Offering is expected to close on or about Feb 18 subject to satisfaction of customary closing conditions.  Full Article

Threshold Pharmaceuticals Inc announces phase 1/2 interim data signaling activity of TH-302 plus bevacizumab (Avastin) in patients with glioblastoma
Monday, 17 Nov 2014 07:00am EST 

Threshold Pharmaceuticals Inc:Says interim data from U.S. investigator-sponsored Phase 1/2 clinical trial of the investigational anticancer drug TH-302 in combination with bevacizumab (Avastin) for treatment of glioblastoma (GBM), most lethal form of brain cancer.Says all patients in study had previously progressed on single-agent bevacizumab, only U.S. Food and Drug Administration (FDA)-approved therapy for GBM patients with progressive disease following prior therapy.As reported by investigator, in total of 22 evaluable patients, best responses included one complete response and three partial responses for a response rate of 18 pct, and ten stable disease assessments for a clinical benefit rate of 64 pct; eight patients had progressive disease.Median progression-free survival was 2.8 months, and median overall survival was 4.6 months.  Full Article

Threshold Pharmaceuticals Inc receives FDA Fast Track Designation for TH-302
Tuesday, 11 Nov 2014 07:00am EST 

Threshold Pharmaceuticals Inc:Says U.S. Food and Drug Administration granted Fast Track designation for TH-302, an investigational anticancer drug.For treatment of previously untreated patients with metastatic or locally advanced unresectable soft tissue sarcoma (STS).FDA established Fast Track designation process to facilitate development and expedite the review of drugs intended to treat serious or life-threatening conditions and that demonstrate the potential to address unmet medical needs.  Full Article

Threshold Pharmaceuticals Inc announces Phase 3 Trial of TH-302 in patients with Advanced Soft Tissue Sarcoma will continue as planned
Monday, 22 Sep 2014 08:00am EDT 

Threshold Pharmaceuticals Inc:Says Independent Data Monitoring Committee (IDMC) has completed planned interim efficacy and safety analyses of unblinded data for company's pivotal Phase 3 clinical trial.Phase 3 Clinical traul of TH-302 in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS).Based on their analyses, which included an assessment of both benefit and risk, the IDMC recommended that the trial should continue as planned to its natural conclusion.  Full Article

BRIEF-Threshold Pharmaceuticals says received preliminary comments from FDA

* On June 2, received preliminary comments from FDA relating to co' s request for a meeting Source text: ( Further company coverage: (Bengaluru Newsroom: +1-646-223-8780)